MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges

    S. Nishida (Tokai, Japan)

    Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…
  • 2025 International Congress

    Detection of novel acoustic biomarkers among Parkinson’s disease patients via an explainable machine learning model

    K. Tsutsumi, P. Chang, S. Isfahani (San Diego, USA)

    Objective: Our aim was to develop and compare machine learning (ML) algorithms for identification of Parkinson’s disease (PD) patients via acoustic analysis of vowel articulation…
  • 2025 International Congress

    Case Report of a Brazilian Family With New VUS for PLAN

    M. Medeiros, M. Augustin (Porto Alegre, Brazil)

    Objective: The aim is to describe a Brazilian family with new VUS of PLA2G6 in two brothers with clinical symptoms of PLAN. Background: PLAN is…
  • 2025 International Congress

    GPi Stimulation shows Immediate Effects in Motor Improvement within Pediatric Patients with Movement Disorders

    A. Brucker, A. Zakharova, S. Seyyed Mousavi, A. Salisbury, J. Olaya, M. Liker, T. Sanger (Orange, USA)

    Objective: This study was conducted in order to determine whether GPi stimulation has immediate clinical effect in patients with dystonia who underwent Deep Brain Stimulation…
  • 2025 International Congress

    Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson’s Disease (PD)

    S. Isaacson, K. Chou, H. Sarva, S. Merchant, C. Scholl, M. Charles, N. Brice, L. Dawson, M. Carlton, S. Vaidya, K. Kieburtz, R. Hauser, A. Ellenbogen (Ann Arbor, USA)

    Objective: Solengepras is a GPR6-inhibitor that is being studied as an investigational treatment for Parkinson’s Disease (PD). Background: GPR6 is a novel G-protein-coupled receptor found…
  • 2025 International Congress

    Gastrointestinal Dysfunction and Levodopa Therapeutic Response in Parkinson’s Disease: A Brazilian Cross-sectional Study

    N. Dos Santos, G. de Vasconcelos, G. Piñeiro, F. Brito, J. Oliveira, S. Baran, J. Costa, E. Muricy, R. Kauark (Salvador, Brazil)

    Objective: To investigate the relation between constipation and the onset time of levodopa therapeutic effect in Parkinson's disease (PD). Background: Levodopa therapeutic response depends on…
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • 2025 International Congress

    Quantifying Bradykinesia in Real-world Practice: A Clinician-friendly Video Analysis Tool for Parkinson’s Disease

    Z. Xu, Y. Tang, J. Wang (Shanghai, China)

    Objective: To develop and validate a video-based automated analysis tool for the objective and quantitive assessment of bradykinesia in Parkinson’s disease (PD). Background: Currently, evaluating…
  • 2025 International Congress

    Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease

    E. Tharp, J. Martinez-Lemus, C. Onuigbo, T. Thomas, C. Green, J. Suescun, T. Le, E. Rodarte, R. Ritter Iii, T. Ellmore, M. Schiess (New York, USA)

    Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…
  • 2025 International Congress

    CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders

    L. Murphy, J. Fortanet, D. Baird, T. Lehmberg, K. Skerry, M. Broadus (Boston, USA)

    Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…
  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley